Shionogi Seeks Approval for COVID-19 Pill in Japan
Newsfrom JapanEconomy Science
Osaka, Feb. 25 (Jiji Press)--Japan's Shionogi & Co. <4507> said Friday that it has filed for health ministry approval for the production and sales of its COVID-19 pill.
If it gets the green light, the pill would be the first oral novel coronavirus drug from a Japanese company. It would contribute to stable supply of COVID-19 treatment drugs in the country.
The drugmaker seeks to use a fast-track process in which approval is given conditionally for practical use of a drug before the completion of clinical trials, with its safety and effectiveness reassessed after the launch.
The pill, which curbs the growth of the coronavirus, will be mainly administered to COVID-19 patients with mild symptoms. One dose per day will be administered for five days in the initial stage of infection.
Shionogi began the final clinical trial for the pill in September last year.
[Copyright The Jiji Press, Ltd.]